As of 2025-07-09, the Intrinsic Value of Samsung Biologics Co Ltd (207940.KS) is 479,962.06 KRW. This 207940.KS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,000,000.00 KRW, the upside of Samsung Biologics Co Ltd is -52.00%.
The range of the Intrinsic Value is 278,856.33 - 1,739,920.53 KRW
Based on its market price of 1,000,000.00 KRW and our intrinsic valuation, Samsung Biologics Co Ltd (207940.KS) is overvalued by 52.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 278,856.33 - 1,739,920.53 | 479,962.06 | -52.0% |
| DCF (Growth 10y) | 717,560.04 - 4,454,181.85 | 1,232,855.14 | 23.3% |
| DCF (EBITDA 5y) | 780,530.89 - 1,381,238.42 | 995,905.83 | -0.4% |
| DCF (EBITDA 10y) | 1,345,221.60 - 2,518,916.17 | 1,765,788.25 | 76.6% |
| Fair Value | 449,455.00 - 449,455.00 | 449,455.00 | -55.05% |
| P/E | 389,187.10 - 688,341.42 | 505,675.09 | -49.4% |
| EV/EBITDA | 333,278.54 - 797,837.81 | 478,259.64 | -52.2% |
| EPV | 73,683.61 - 101,220.47 | 87,452.02 | -91.3% |
| DDM - Stable | 266,095.22 - 2,037,866.31 | 1,151,981.17 | 15.2% |
| DDM - Multi | 624,169.45 - 3,729,579.53 | 1,070,750.32 | 7.1% |
| Market Cap (mil) | 71,170,000.00 |
| Beta | 0.22 |
| Outstanding shares (mil) | 71.17 |
| Enterprise Value (mil) | 71,837,440.00 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.76% |
| Cost of Debt | 4.25% |
| WACC | 6.69% |